Mr. James Passin is a former hedge fund and private equity fund manager at New York-based Firebird Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed significant equity and debt investment into biotech companies, with a particular focus on cancer immunotherapy. James was a co-founder and director of Mindset Pharma Inc., a psychedelic biotechnology company acquired by Otsuka Pharmaceutical in 2023.  Mr. Passin is a graduate of the Listed Company Director program, Singapore Institute of Directors; has a Certificate in Corporate Governance from the Mongolian Corporate Governance Institute; and is a Chartered Market Technician and Member of The CMT Association.

Mr. Kovan has over 30 years of experience in biopharmaceuticals commercial development. He recently served as Corporate Development Partner with Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012 that specializes in corporate development, technology licensing, and business planning. He is an experienced former biotech CEO and board member, and founder of biotechnology companies including the former Avax Technologies, Inc. Mr. Kovan’s professional background includes several years in technology transfer with Thomas Jefferson University, Strategic Marketing with GlaxoSmithKline, and Global New Product Development with Wyeth-Ayerst Pharmaceuticals. His therapeutic experience includes infectious disease, antivirals, oncology, vaccines, cell/gene therapy, and gene editing. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets, and has worked in Europe for several years.

Dr. David Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He cofounded cancer immunotherapy company AVAX Technologies, is the inventor of the cancer vaccines MVax™ and OVax™, and served as Chief Medical Officer 2005-2008. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. He has ten issued patents dealing with cancer vaccines. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.

Craig Loverock is a Chartered Professional Accountant with over 20 years’ experience in accounting and finance roles in Canada, the United States, and the United Kingdom. He brings with him public company reporting and transactional experience, as well as having provided CFO consulting services to a number of private high growth technology businesses, serving as the Senior Financial Advisor to the Chairman at Magna International, and acting as the Chief Compliance Officer and CFO for a private equity firm. Mr. Loverock received his B.Comm (Hons) from Carleton University in 1994 and received his Chartered Accountant’s designation from the Institute of Chartered Accountants, Ontario in 1997. He is currently the treasurer of the Durham Community Foundation.

Anthony brings more than two decades of senior corporate leadership with expertise in strategic planning, financing, and M&A with broad industry experience, including manufacturing, cannabis, and oil and gas. He is a partner at HighMont Advisors and most recently was co-founder and CEO of Cannex Capital Group Inc. (“Cannex”) a pioneering US cannabis company, before its 2019 acquisition of 4Front Holdings Ltd. to create 4Front Ventures (CSE:FFNT), a leading multi-state cannabis operator. Prior to Cannex, Anthony was CEO, President and a director of IBC Advanced Alloys Corp. (“IBC”)(TSX-V:IB) a high performance alloys company serving the defense, aerospace, automotive, and precision manufacturing sectors. He currently serves on the board of Sanatana Resources Inc. (TSX.V:STA) and has a B.A. (Econ.) from the University of British Columbia, an M.Arch. from Dalhousie University and an MBA from the Cranfield School of Management in the UK.